Tests pumitamig, with or without ipilimumab, in liver cancer
Tests pumitamig alone or with ipilimumab in adults with advanced liver cancer.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Key facts
- Where
- Barcelona, Madrid, and Pamplona, SpainSee the 5 sites
- Phase
- Phase 1/2
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
- Clinica Universidad de NavarraMadrid, SpainTaking people
- Hospital General Universitario Gregorio MarañónMadrid, SpainTaking people
- Hospital Universitario HM SanchinarroMadrid, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07291076EU 2025-523602-33-00
- Record updated
- 23 October 2026
- Original description
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)Read full original descriptionShow less
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Inclusion: Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC); Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Participants must have no prior systemic therapy for advanced/ unresectable HCC; Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Exclusion: Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence; Participants must not have an organ transplant or autoimmune disease; Other protocol-defined Inclusion/Exclusion criteria apply.